![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (87)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Qiuying Li, Hua Huo, Wenli Hu, Yin Sui & Yunbiao Tang. (2020) Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions. Drug Design, Development and Therapy 14, pages 5167-5177.
Read now
Read now
Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Masatsugu Moriwaki, Yoichiro Otake, Kaku Akamatsu, Tomo Okochi, Shigeki Hirano, Toshihiko Funahashi, Momoko Okuda, Hideaki Tabuse, Kiyoshi Fujita & Nakao Iwata. (2017) Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial. Neuropsychiatric Disease and Treatment 13, pages 117-125.
Read now
Read now
Kaida Jiang, Lingjiang Li, Xueyi Wang, Maosheng Fang, Jianfei Shi, Qiuyun Cao, Jincai He, Jinan Wang, Weihao Tan & Cuili Hu. (2017) Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population. Neuropsychiatric Disease and Treatment 13, pages 515-526.
Read now
Read now
Eiji Kirino. (2012) Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Preference and Adherence 6, pages 853-861.
Read now
Read now
Mazen K Ali & Raymond W Lam. (2011) Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment 7, pages 39-49.
Read now
Read now
Larry Ereshefsky, Delphine Saragoussi, Nicolas Despiégel, Karina Hansen, Clément François & Khaled Maman. (2010) The 6-month persistence on SSRIs and associated economic burden. Journal of Medical Economics 13:3, pages 527-536.
Read now
Read now
Alan G. Wade, Delphine Saragoussi, Nicolas Despiégel, Clément François, Florent Guelfucci & Mondher Toumi. (2010) Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK. Current Medical Research and Opinion 26:5, pages 1161-1170.
Read now
Read now
J.P. Boulenger, A. Hermes, A.K.T. Huusom & E. Weiller. (2010) Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. Current Medical Research and Opinion 26:3, pages 605-614.
Read now
Read now
Rodrigo CL Edelmuth, Michael A Nitsche, Linamara Battistella & Felipe Fregni. (2010) Why do some promising brain-stimulation devices fail the next steps of clinical development?. Expert Review of Medical Devices 7:1, pages 67-97.
Read now
Read now
Clinton D Kilts, Alan G Wade, Henning F Andersen & Thomas E Schlaepfer. (2009) Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opinion on Pharmacotherapy 10:6, pages 927-936.
Read now
Read now
SS Stamouli, A Yfantis, E Lamboussis, A Liakouras, V Lagari, M Tzanakaki, D Giailoglou, M Legault & IA Parashos. (2009) Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients. Expert Opinion on Pharmacotherapy 10:6, pages 937-945.
Read now
Read now
Sidney H. Kennedy, Henning F. Andersen & Michael E. Thase. (2009) Escitalopram in the treatment of major depressive disorder: A meta-analysis. Current Medical Research and Opinion 25:1, pages 161-175.
Read now
Read now
Vasilios G. Masdrakis, Panagiotis Oulis, Anastasios V. Kouzoupis, George V. Masdrakis & Constantin R. Soldatos. (2009) Bilateral ankle oedema in a patient taking escitalopram. The World Journal of Biological Psychiatry 10:4-3, pages 939-941.
Read now
Read now
Cyril Höschl & Jaromír Švestka. (2008) Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics 8:4, pages 537-552.
Read now
Read now
Joseph Zohar. (2008) Escitalopram in the treatment of obsessive–compulsive disorder. Expert Review of Neurotherapeutics 8:3, pages 339-349.
Read now
Read now
Raymond W Lam & Lieven Annemans. (2007) Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, pages 559-576.
Read now
Read now
Silvio R Bareggi, Emanuela Mundo, Bernardo Dell'Osso & A Carlo Altamura. (2007) The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 741-753.
Read now
Read now
A. Wade, K. Gembert & I. Florea. (2007) A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Current Medical Research and Opinion 23:7, pages 1605-1614.
Read now
Read now
Luchezar G. Hranov. (2007) Comorbid anxiety and depression: illumination of a controversy. International Journal of Psychiatry in Clinical Practice 11:3, pages 171-189.
Read now
Read now
Alan Wade & Henning Friis Andersen. (2006) The onset of effect for escitalopram and its relevance for the clinical management of depression. Current Medical Research and Opinion 22:11, pages 2101-2110.
Read now
Read now
Stuart A. Montgomery. (2006) Guidelines in major depressive disorder, and their limitations. International Journal of Psychiatry in Clinical Practice 10:sup3, pages 3-9.
Read now
Read now
Articles from other publishers (66)
Juntao Yin, Xiaoyong Song, Chaoyang Wang, Xuhong Lin & Mingsan Miao. (2023) Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis. BMC Psychiatry 23:1.
Crossref
Crossref
Se Jong Oh, Namhun Lee, Kyung Rok Nam, Kyung Jun Kang, Sang Jin Han & Jae Yong Choi. (2023) Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression. Molecular Imaging and Biology 25:4, pages 735-743.
Crossref
Crossref
N Simple Santi, Sashi B Biswal, Birendra Narayan Naik, Jyoti Prakash Sahoo & Bhabagrahi Rath. (2023) Metabolic Effects of Antidepressants: Results of a Randomized Study’s Interim Analysis. Cureus.
Crossref
Crossref
N Simple Santi, Sashi B Biswal, Birendra Narayan Naik, Jyoti Prakash Sahoo & Bhabagrahi Rath. (2023) Quality of Life and Medication Adherence in Patients With Major Depressive Disorder: An Interim Analysis of a Randomized Study. Cureus.
Crossref
Crossref
N Simple Santi, Sashi Bhusan Biswal, Birendra Narayan Naik, Jyoti Prakash Sahoo & Bhabagrahi Rath. (2023) An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder. Cureus.
Crossref
Crossref
Vishal Bhatia, Ashwani K. Dhingra, Bhawna Chopra & Kumar Guarve. (2023) A Review of Clinical Studies Assessing the Therapeutic Efficacy of
Escitalopram: A Step Towards Development. CNS & Neurological Disorders - Drug Targets 22:1, pages 41-50.
Crossref
Crossref
Tatiyana Mandal, Laxminarayana Kurady Bairy, Podila Satya Venkata Narasimha Sharma & Vijaya Lakshmi Valaparla. (2021) Impact of gender, depression severity and type of depressive episode on efficacy and safety of escitalopram: an observational study on major depressive disorder patients in southern India. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 57:1.
Crossref
Crossref
Xiaoliang Wang, Yimin Fan, Guanjun Li & Huafang Li. (2021) The efficacy of escitalopram in major depressive disorder: a multicenter randomized, placebo-controlled double-blind study. International Clinical Psychopharmacology 36:3, pages 133-139.
Crossref
Crossref
Qianqian He, Yan Mei, Yuanyuan Liu, Zhuo Yuan, Jian Zhang, Hong Yan, Li Shen & Yong Zhang. (2019) Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder. Journal of Clinical Psychopharmacology 39:2, pages 117-123.
Crossref
Crossref
. 2019. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
119
.
Ji-hua Xu & Peng Jiang. (2018) Efficacy of escitalopram oxalate for patients with post-stroke depression. Medicine 97:14, pages e0219.
Crossref
Crossref
Qianqian He, Zhuo Yuan, Yuanyuan Liu, Jian Zhang, Hong Yan, Li Shen, Xingguang Luo & Yong Zhang. (2017) Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. Pharmacogenetics and Genomics 27:8, pages 279-284.
Crossref
Crossref
Tianmei Si, Gang Wang, Fude Yang, Yiru Fang, Maosheng Fang, Jijun Li, Jicheng Dong, Xinhua Shen, Jianmin Zhuo, Qing Rui, Jinan Wang & Hu Cuili. (2017) Efficacy and safety of escitalopram in treatment of severe depression in Chinese population. Metabolic Brain Disease 32:3, pages 891-901.
Crossref
Crossref
. 2017. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
111
.
David F. Lehmann & Sarabeth Wojnowicz. (2015) The Evergreening of Biopharmaceuticals: Time to Defoliate. The Journal of Clinical Pharmacology 56:4, pages 383-389.
Crossref
Crossref
Eiji Kirino. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
465
476
.
Ai Leng Khoo, Hui Jun Zhou, Monica Teng, Liang Lin, Ying Jiao Zhao, Lay Beng Soh, Yee Ming Mok, Boon Peng Lim & Kok Peng Gwee. (2015) Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants. CNS Drugs 29:8, pages 695-712.
Crossref
Crossref
. 2015. Therapie Psychischer Erkrankungen. Therapie Psychischer Erkrankungen
e1
e96
.
Barbara Nussbaumer, Laura C. Morgan, Ursula Reichenpfader, Amy Greenblatt, Richard A. Hansen, Megan Van Noord, Linda Lux, Bradley N. Gaynes & Gerald Gartlehner. (2014) Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis. CNS Drugs 28:8, pages 699-712.
Crossref
Crossref
Marianna Purgato, Davide Papola, Chiara Gastaldon, Carlotta Trespidi, Laura R Magni, Carla Rizzo, Toshi A Furukawa, Norio Watanabe, Andrea Cipriani & Corrado Barbui. (2014) Paroxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2014:4.
Crossref
Crossref
. 2014. Therapie Psychischer Erkrankungen. Therapie Psychischer Erkrankungen
1
91
.
Ursula Reichenpfader, Gerald Gartlehner, Laura C. Morgan, Amy Greenblatt, Barbara Nussbaumer, Richard A. Hansen, Megan Van Noord, Linda Lux & Bradley N. Gaynes. (2013) Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis. Drug Safety 37:1, pages 19-31.
Crossref
Crossref
Siegfried Kasper & Stuart MontgomeryStuart Montgomery. 2013. Treatment‐resistant Depression. Treatment‐resistant Depression
91
105
.
Klaus P. Bøgesø & Connie Sánchez. 2012. Analogue‐Based Drug Discovery III. Analogue‐Based Drug Discovery III
269
294
.
Martin Lieb, Rainer Rupprecht & Thomas C. Baghai. (2012) Für jeden Patienten den optimalen Wirkstoff finden. NeuroTransmitter 23:12, pages 26-38.
Crossref
Crossref
Anjana Bose, Joyce Tsai & Dayong Li. (2012) Early Non-Response in Patients with Severe Depression. Clinical Drug Investigation 32:6, pages 373-385.
Crossref
Crossref
Dan J. Stein & Ana Garcia Lopez. (2011) Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Advances in Therapy 28:11, pages 1021-1037.
Crossref
Crossref
Alessandro Serretti, Sara Gibiino & Antonio Drago. (2011) Specificity profile of paroxetine in major depressive disorder: Meta-regression of double-blind, randomized clinical trials. Journal of Affective Disorders 132:1-2, pages 14-25.
Crossref
Crossref
Eric Q Wu, Andrew P YuVeronique LauzonKarthik RamakrishnanMaryna MarynchenkoRym Ben-HamadiSteven Blum & M Haim Erder. (2011) Economic Impact of Therapeutic Substitution of a Brand Selective Serotonin Reuptake Inhibitor with an Alternative Generic Selective Serotonin Reuptake Inhibitor in Patients with Major Depressive Disorder. Annals of Pharmacotherapy 45:4, pages 441-451.
Crossref
Crossref
George I. Papakostas & Klaus Larsen. (2010) Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. European Archives of Psychiatry and Clinical Neuroscience 261:3, pages 147-156.
Crossref
Crossref
Stuart Montgomery, Thomas Hansen & Siegfried Kasper. (2010) Efficacy of escitalopram compared to citalopram: a meta-analysis. The International Journal of Neuropsychopharmacology 14:02, pages 261-268.
Crossref
Crossref
Jian-Jun Ou, Guang-Lei Xun, Ren-Rong Wu, Le-Hua Li, Mao-Sheng Fang, Hong-Geng Zhang, Shi-Ping Xie, Jian-Guo Shi, Bo Du, Xue-Qin Yuan & Jing-Ping Zhao. (2010) Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology 213:2-3, pages 639-646.
Crossref
Crossref
J.-C. Chauvet-Gélinier. (2010) Efficacité de l’escitalopram vs paroxétine sur les formes de dépressions sévères avec symptômes anxieux associés. Données issues de l’étude « Boulenger » : escitalopram versus paroxétine. L'Encéphale 36:5, pages 425-432.
Crossref
Crossref
Karly P. Garnock-Jones & Paul L. McCormack. (2010) Escitalopram. CNS Drugs 24:9, pages 769-796.
Crossref
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref
Crossref
C. Spadone. (2009) Efficacité de l’escitalopram et sévérité de la dépression : nouvelles données. L'Encéphale 35:6, pages 577-585.
Crossref
Crossref
S. Mouchabac. (2009) Dépressions sévères : traitements pharmacologiques. L'Encéphale 35, pages S319-S324.
Crossref
Crossref
Susan G. Kornstein, Dayong Li, Yongcai Mao, Sara Larsson, Henning F. Andersen & George I. Papakostas. (2014)
Escitalopram Versus SNRI Antidepressants in the Acute Treatment of Major Depressive Disorder:
Integrative Analysis of Four Double-Blind, Randomized Clinical Trials
. CNS Spectrums 14:6, pages 326-333.
Crossref
Crossref
David S. Baldwin, Dan J. Stein, Ornah T. Dolberg & Borwin Bandelow. (2009) How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology: Clinical and Experimental 24:4, pages 269-275.
Crossref
Crossref
Stuart A. Montgomery & Hans-Jürgen Möller. (2009) Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. International Clinical Psychopharmacology 24:3, pages 111-118.
Crossref
Crossref
Andrea Cipriani, Claudio Santilli, Toshi A Furukawa, Alessandra Signoretti, Atsuo Nakagawa, Hugh McGuire, Rachel Churchill & Corrado Barbui. (2009) Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2016:5.
Crossref
Crossref
Andrea Cipriani, Teresa La Ferla, Toshi A Furukawa, Alessandra Signoretti, Atsuo Nakagawa, Rachel Churchill, Hugh McGuire & Corrado Barbui. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Siegfried Kasper, David S. Baldwin, Sara Larsson Lönn & Jean-Philippe Boulenger. (2009) Superiority of escitalopram to paroxetine in the treatment of depression. European Neuropsychopharmacology 19:4, pages 229-237.
Crossref
Crossref
C. Spadone. (2009) Formes sévères de dépression : efficacité de l’escitalopram. L'Encéphale 35:2, pages 152-159.
Crossref
Crossref
A.G. Wade, T.E. Schlaepfer, H.F. Andersen & C.D. Kilts. (2009) Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of Psychiatric Research 43:5, pages 568-575.
Crossref
Crossref
Andrea Cipriani, Toshiaki A Furukawa, Georgia Salanti, John R Geddes, Julian PT Higgins, Rachel Churchill, Norio Watanabe, Atsuo Nakagawa, Ichiro M Omori, Hugh McGuire, Michele Tansella & Corrado Barbui. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet 373:9665, pages 746-758.
Crossref
Crossref
Max Schmauß, Elisabeth Schramm & Mathias Berger. 2009. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
131
169
.
P. Giacobbe & S. Kennedy. 2009. Textbook of Stereotactic and Functional Neurosurgery. Textbook of Stereotactic and Functional Neurosurgery
2925
2941
.
Vasilios G. Masdrakis, Panagiotis Oulis, Andreas Florakis, Theodoros Valamoutopoulos, Maria Markatou & George N. Papadimitriou. (2008) The Safety of the Electroconvulsive Therapy-Escitalopram Combination. The Journal of ECT 24:4, pages 289-291.
Crossref
Crossref
Pratap Chokka & Mark Legault. (2008) Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial. Depression and Anxiety 25:12, pages E173-E181.
Crossref
Crossref
SH Kennedy. (2008) Treating each and every depressed patient. Journal of Psychopharmacology 22:7_suppl, pages 19-23.
Crossref
Crossref
Koen Demyttenaere, Henning Friis Andersen & Elin Heldbo Reines. (2008) Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. International Clinical Psychopharmacology 23:5, pages 276-286.
Crossref
Crossref
Raymond W. Lam, Henning F. Andersen & Alan G. Wade. (2008) Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. International Clinical Psychopharmacology 23:4, pages 181-187.
Crossref
Crossref
J.P. Boulenger. (2008) D’une indication à l’autre : intérêt des études long terme. L'Encéphale 34, pages S115-S119.
Crossref
Crossref
B. Millet. (2008) Place de l’escitalopram dans les épisodes dépressifs sévères. L'Encéphale 34, pages S111-S114.
Crossref
Crossref
Gerald Gartlehner, Patricia Thieda, Richard A Hansen, Bradley N Gaynes, Angela DeVeaugh-Geiss, Erin E Krebs & Kathleen N Lohr. (2008) Comparative Risk for Harms of Second-Generation Antidepressants. Drug Safety 31:10, pages 851-865.
Crossref
Crossref
Malcolm Lader. (2007) Limitations of current medical treatments for depression: Disturbed circadian rhythms as a possible therapeutic target. European Neuropsychopharmacology 17:12, pages 743-755.
Crossref
Crossref
P. Van Dijck. (2007) Escitalopram, un développement clinique complet. L'Encéphale 33, pages 134-139.
Crossref
Crossref
Stuart A. Montgomery, David S. Baldwin, Pierre Blier, Naomi A. Fineberg, Siegfried Kasper, Malcolm Lader, Raymond W. Lam, Jean-Pierre Lépine, Hans-Jürgen Möller, David J. Nutt, Frederic Rouillon, Alan F. Schatzberg & Michael E. Thase. (2007) Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology 22:6, pages 323-329.
Crossref
Crossref
Silvio R Bareggi, Emanuela Mundo, Bernardo Dell'Osso & A Carlo Altamura. (2007) The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 741-753.
Crossref
Crossref
David S Baldwin, Elin Heldbo Reines, Christina Guiton & Emmanuelle Weiller. (2016) Escitalopram Therapy for Major Depression and Anxiety Disorders. Annals of Pharmacotherapy 41:10, pages 1583-1592.
Crossref
Crossref
Stuart A. Montgomery & Siegfried Kasper. (2007) Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. International Clinical Psychopharmacology 22:5, pages 283-291.
Crossref
Crossref
Christina F. Bisgaard, Magdalena N. Jayatissa, Jan J. Enghild, Connie Sanchéz, Roman Artemychyn & Ove Wiborg. (2007) Proteomic Investigation of the Ventral Rat Hippocampus Links DRP-2 to Escitalopram Treatment Resistance and SNAP to Stress Resilience in the Chronic Mild Stress Model of Depression. Journal of Molecular Neuroscience 32:2, pages 132-144.
Crossref
Crossref
Pedro J. Garcia Ruiz, Iria Cabo, Pablo Garcia Bermejo & Pablo Carnal. (2007) Escitaloparm-Induced Paroxysmal Dystonia. Clinical Neuropharmacology 30:2, pages 124-126.
Crossref
Crossref
Sohita Dhillon, Lesley J Scott & Greg L Plosker. (2006) Escitalopram. CNS Drugs 20:9, pages 763-790.
Crossref
Crossref
Jonathan Rabinowitz, Janet Williams, Nanco Hefting, Ariana Anderson, Brianne Brown, Dong-Jing Fu, Bashkim Kadriu, Alan Kott, Atul Mahableshwarkar, Jan Sedway, David Williamson, Christian Yavorsky & Nina R. Schooler. (2022) Consistency Checks to Improve Measurement with the Hamilton Rating Scale for Anxiety (HAM-A). SSRN Electronic Journal.
Crossref
Crossref